Clinical Trial Update: Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating anlotinib hydrochloride combined with sintilimab for advanced hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anlotinib hydrochloride (anlotinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Advanced Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN